

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1331-222

WOLPE et al.

JUN 03 2002

Group Art Unit: 1644

C# M#

Serial No. 08/832,443

Examiner: D.A. Saunders

Filed: April 3, 1997

Date: June 3, 2002

Title: INHIBITOR OF STEM CELL PROLIFERATION AND USES THEREOF

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

AMENDMENT UNDER 37 CFR §1.111

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment **18** minus highest number
previously paid for **123** (at least 20) = 0 x \$ 18.00 \$ 0.00

Independent claims after amendment **3** minus highest number
previously paid for **25** (at least 3) = 0 x \$ 84.00 \$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00

Petition is hereby made to extend the current due date so as to cover the filing date of this
paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00

☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) \$ 0.00

☐ Please enter the previously unentered, filed

☐ Submission attached

Subtotal \$ **0.00**

If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: **Substitute paper and computer readable forms of the Sequence Listing; and Stryer et al.,
Biochemistry, 2nd ed. (pp. 43-63)** 0.00

TOTAL FEE ENCLOSED \$ **0.00**

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
GRT:ap

NIXON & VANDERHYE P.C.
By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUN 06 2002

In re Patent Application of

WOLPE et al.

Appln. No. 09/832,443

Filed: April 3, 1997

Atty. Ref.: 1331-222r

Group Art Unit: 1644

Examiner: D.A. Saunders

TECH CENTER 1600/2900

FOR: INHIBITOR AND STIMULATOR OF STEM CELL PROLIFERATION AND USES THEREOF

* * *

AMENDMENT UNDER 37 CFR § 1.111

Monday, June 3, 2002

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the pending Office Action (Paper No. 32) mailed March 1, 2002, entry and consideration of the following amendments and remarks are respectfully requested.

IN THE SPECIFICATION

Kindly enter the following amended paragraphs.

Page 24, third paragraph,

The invention also includes a method of inhibiting or stimulating stem cell proliferation comprising contacting hematopoietic cells with a peptide selected from the group of hemorphin peptides having the sequence:

Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-Phe (SEQ ID NO:4),

Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg (SEQ ID NO:5),

Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln (SEQ ID NO:6),

Leu-Val-Val-Tyr-Pro-Trp-Thr (SEQ ID NO:7),

Leu-Val-Val-Tyr-Pro-Trp (SEQ ID NO:8),

Leu-Val-Val-Tyr-Pro (SEQ ID NO:9),

Val-Val-Tyr-Pro-Trp-Thr-Gln (SEQ ID NO:10),

Tyr-Pro-Trp-Thr-Gln-Arg-Phe (SEQ ID NO:11),

Tyr-Pro-Trp-Thr-Gln-Arg (SEQ ID NO:12),